Germane Facts about Germanium Sesquioxide: I. Chemistry and Anticancer Properties

Journal of Alternative and Complementary Medicine

Volumn 10, Issue 2, 2004, Pages 337-344

  Kaplan, Bonnie J ^a,d   Parish, W Wesley ^b   Andrus, G Merrill ^b   Simpson, J Steven A ^a   Field, Catherine J ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b Parish Chemical Company   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 CARBAMOYL 1 PHENYLETHYLGERMANIUM SESQUIOXIDE; 2 CARBAMOYL 1 PHENYLETHYLGERMANIUM SESQUISULFIDE; ANTINEOPLASTIC AGENT; BIS(2 CARBOXYETHYLGERMANIUM)SESQUIOXIDE; GAMMA INTERFERON; ORGANOGERMANIUM COMPOUND; SPIROGERMANIUM; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CHEMICAL ANALYSIS; CHEMICAL MODIFICATION; CLINICAL TRIAL; CYTOKINE RELEASE; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; HISTORY; HUMAN; LUNG CARCINOMA; LYMPHOCYTE ACTIVATION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL LITERATURE; METASTASIS; NATURAL KILLER CELL; NEPHROTOXICITY; NONHUMAN; ORGANIC CHEMISTRY; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING;

EID: 1942542344     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/107555304323062329     Document Type: Review

References (69)

1. Anger F, Anger JP, Guillou L, Papillon A. Subchronic oral toxicity (six months) of carboxyethylgermanium sesquioxide in rats. Appl Organo Chem 1992;6:267-272.
2. Asai K. Organic Germanium, A Medical Godsend. trans. Center BI., Tokyo: Kogakusha, Ltd.
3. Asai K. (1980) Miracle Cure: Organic Germanium. New York: Japan Publications, Inc.
4. Asano K, Yamano M, Haruyama K, Ikawa E, Nakano K, Kurono M, Wada O. Influence of propagermanium (SK-818) on chemically induced renal lesions in rats. J Toxicol Sci 1994;19:131-143.
5. Aso H, Suzuki F, Ebina T, Ishida N. Antiviral activity of carboxyethylgermanium sesquioxide (Ge-132) in mice infected with influenza virus. J Biol Response Mod 1989;8:180-189.
6. Aso H, Suzuki F, Yamaguchi T, Hayashi Y, Ebina T, Ishida N. Induction of interferon and activation of NK cells and macrophages in mice by oral administration of Ge-132, an organic germanium compound. Microbiol Immunol 1985;29:65-74.
7. Davydov V. Germanium. Picoperl A, trans. New York: Gordon and Breach, Science Publishers.
8. Eisenhauer E, Kerr I, Bodurtha A, Iscoe N, McCulloch P, Pritchard K, Quirt K. A phase II study of spirogermanium in patients with metastatic malignant melanoma.: An NCI Canada Clinical Trials Group study. Invest New Drugs 1985a;3:303-305.
9. Eisenhauer E, Quirt I, Connors JM, Maroun J, Skillings J. A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma: An NCI Canada Clinical Trials Group study. Invest New Drugs 1985b;3:307-310.
10. Ettinger DS, Finkelstein DM, Donehower RC, Chang AY, Green M, Blum R, Han RG, Ruckdeschel JC. Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): An Eastern Cooperative Oncology Group study. Med Pediatr Oncol 1989;17:197-201.
11. Falkson G, Falkson HC. Phase II trial of spirogermanium for treatment of advanced breast cancer. Cancer Treat Rep 1983;67:189-190.
12. Fujita H, Kurono M, Toyoshima S. Effect of 3-oxygermylpropionic acid polymer (SK-818) on the incidence of spontaneous leukemia in AKR mice. Pharmacometrics 1990;39:389-395.
13. Fujita H, Seto Y. Antiviral activity of 3-oxygermylpropionic acid polymer (SK-818). Pharmacometrics 1990;39:385-388.
14. Gerber GB, Leonard A. Mutagenicity, carcinogenicity and teratogenicity of germanium compounds. Mutat Res 1997;387:141-146.
15. Glocking F. The Chemistry of Germanium. New York: Academic Press, 1969.
16. Goodman S. Germanium The Health and Life Enhancer. Wellingborough, Northampton: Thorsons Publishing Company, 1988.
17. Goodwin JW, Crowley J, Tranum B, Vance R, Slavik M, Balcerzak S, Hacker D. Phase II trial of spirogermanium in central nervous system tumors: A Southwest Oncology Group study. Cancer Treat Rep 1987;71:99-100.
18. Hara S, Hayashi N, Hirano S, Zhong X-N, Yasuda S, Komae H. Determination of germanium in some plants and animals. Zeitschrifte fur Naturforschung 1990;45C:1250-1251.
19. Henry MC, Rosen E, Port CD, Levine BS. Toxicity of spirogermanium in mice and dogs after iv or im administration. Cancer Treat Rep 1980;64:1207-1210.
20. Hess B, Raisin J, Zimmermann A, Horber F, Bajo S, Wyttenbach A, Jaeger P. Tubulointerstitial nephropathy persisting 20 months after discontinuation of chronic intake of germanium lactate citrate. Am J Kidney Dis 1993;21:548-552.
21. Heuper W. Effects of overdoses of germanium dioxide upon the blood and tissues of rabbits. Am J Med Sci 1931;181:820-830.
22. Ikemoto K, Kobayashi M, Fukimoto T, Morimatsu M, Pollard RB, Suzuki F. 2-carboxyethylgermanium sesquioxide, a synthetic organogermanium compound, as an inducer of contrasuppressor T cells. Experientia 1996;15:159-166.
23. Jang JJ, Cho KJ, Lee YS, Bae JH. Modifying responses of allyl sulfide, indole-3-carbinol and germanium in a rat multi-organ carcinogenesis model. Carcinogenesis 1991;4:691-695.
24. Jao S-W, Lee W, Ho Y-S. Effect of germanium on 1, 2-dimethyl-hydrazine-induced intestinal cancer in rats. Dis Colon Rectum 1990;33:99-104.
25. Kamen B. Germanium, A New Approach to Immunity. Larkspur, CA: Nutritional Encounter, Inc., 1987.
26. Kobayashi H, Komuro T, Furue H. Effect of combination immunochemotherapy with an organogermanium compound, Ge-132, and antitumor agents on C57BL/6 mice bearing Lewis lung carcinoma (3LL). Gan To Kagaku Ryoho 1986;13:2588-2593.
27. Kobayashi K, Ohchi N, Sanai T, Oh Y, Onoyama K, Fujishima M. Germanium nephropathy: Light, immunofluorescence, electron microscope and X-ray dispersive analytical study. J Clin Electron Microsc 1989;22:1-11.
28. Kumano N, Ishikawa T, Koinumaru S, Kikumoto T, Suzuki S, Nakai Y, Konno K. Antitumor effect of the organogermanium compound Ge-132 on the Lewis lung carcinoma (3LL) in C57BL/6 (B6) mice. Tohoku J Exp Med 1985;146:97-104.
29. Kuwabara M, Ohbe S, Yukawa M. Effect of germanium, polytrans-[2-carboxyethyl] germasesquioxane on natural killer (NK) activity in dogs. J Vet Med Sci 2002;64:719-721.
30. Lesbre M, Maxerolles P, Satge J. The Organic Compounds of Germanium. New York: Interscience, 1971.
31. Lewis BL, Frolich PN, Andreae MO. Methylgermanium in natural waters. Nature 1985;313:303-305.
32. Mainwaring MG, Poor C, Zander DS, Harman E. Complete remission of pulmonary spindle cell carcinoma after treatment with oral germanium sesquioxide. Chest 2000;117:591-593.
33. Massey P. Dietary supplements. Med Clin North Am 2002;86:127-147.
34. McMaster M, Greco F, Johnson D, Hainsworth J. An evaluation of combination 5-fluorouracil and spirogermanium in the treatment of advanced colorectal carcinoma. Invest New Drugs 1990;8:87-92.
35. The Merck Index. Vol. 7979. Whitehouse Station, N.J.: Merck & Co, Inc., 1996.
36. Ming X, Yin H, Zhu Z. Effect of dietary selenium and germanium on the precancerous lesion in rat glandular stomach induced by N-methyl-N′ -nitro-N-nitrosoguanidine. Zhonghua Wai Ke Za Zhi 1996;34:221-223.
37. Mino Y, Ota N, Sakio S, Shimomura S. Determination of germanium in medicinal plants by atomic absorption spectrometry with electrothermal atomization. Chem Pharmacol Bull 1980;28:2687-2691.
38. Mirabelli C, Badger A, Sung C, Hillegass L, Sung C, Johnson R, Picker D, Schwartz D, Dorman J, Martellucci S. Pharmacological activities of spirogermanium and other structurally related azaspiranes: Effects on tumor cell and macrophage functions. Anticancer Drug Des 1989;3:231-242.
39. Mironov VF. Review: Synthetic studies with organic compounds of germanium. Main Group Metal Chem 1989;12:355-388.
40. Mironov VF, Berliner EM, Gar TK. Reactions of trichlorogermane with acrylic acid and its derivatives. (Translation). Zh Obshch Khim 1967;37:911-912.
41. Mironov VF, Gar TK. Trichlorogermane Chemistry. J Organometal Chem Rev A 1968;3:311-321.
42. Miyao K, Onishi T, Asai K, Tomizawa S, Suzuki F. Toxicology and Phase I studies on a novel organogermanium compound, Ge-132. In: Nelson JD, Grassi C, eds., Current Chemotherapy and Infectious Diseases. Washington, D.C.: American Society of Microbiology, 1980:1527-1529.
43. Mueller R. Erythropoietic action, cumulative effects and elimination of germanium dioxide. Am J Med Sci 1922;163:364-372.
44. Nagata N, Yoneyama T, Yanagida K. Accumulation of germanium in the tissues of a long-term user of germanium preparation dead of acute renal failure. J Toxicol Sci 1985;10:333-341.
45. Nakada Y, Kosaka T, Kuwabara M, Tanaka S, Sato K, Koide F. Effects of 2-carboxyethylgermanium sesquioxide (Ge-132) as an immunological modifier of post-surgical immunosuppression in dogs. J Vet Med Sci 1993;55:795-799.
46. Obara K, Saito T, Sato H, Yamakage K, Watanabe T, Kakizawa M, Tsukamoto T, Kobayashi K, Hongo M, Yoshinaga K. Germanium poisoning: Clinical symptoms and renal damage caused by long-term intake of germanium. Jpn J Med 1991;30:67-72.
47. Okuda S, Kiyama S, Oh Y, Shimamatsu K, Oochi N, Kobayashi K, Nanishi F, Fujima S, Onoyama K, Fujishima M. Persistent renal dysfunction induced by chronic intake of germanium-containing compounds. Curr Ther Res Clin Exp 1987;41:265-275.
48. Rice LM, Wheeler WJ, Geschickter CF. Synthesis of 4,4-diakyl-4-4-germacyclohexanone and 8,8-diakyl-8-germanspiro 8 (4.5) decanes. J Hetrocyclic Chem 1984;11:1041-1047.
49. Saiers JH, Slavik M, Stephens RL, Crawford ED. Therapy for advanced renal cell cancer with spirogermanium: A Southwest Oncology Group study. Cancer Treat Rep 1987;71:207-208.
50. Sanai T, Okuda S, Onoyama K, Oochi N, Takaichi S, Mizuhira V, Fujishima M. Chronic tubulointerstitial changes induced by germanium dioxide in comparison with carboxyethylgermanium sesquioxide. Kidney Int 1991a;40:882-890.
51. Sanai T, Onoyama K, Osato S, Motomura K, Oochi N, Oh Y, Okuda S, Takaichi S, Fujishima M. Dose dependency of germanium dioxide-induced nephrotoxicity in rats. Nephron 1991b; 57:349-354.
52. Sato I, Nishimura T, Kakimoto N, Suzuki H, Tanaka N. Prevention of pulmonary metastasis of Lewis lung carcinoma and activation of murine macrophages by a novel organic germanium compound. PCAGeS. Biol Response Mod 1988;7:1-5.
53. Sato I, Yuan BD, Nishimura T, Tanaka N. Inhibition of tumor growth and metastasis in association with modification of immune response by novel organic germanium compounds. J Biol Response Mod 1985;4:159-168.
54. Sawai K, Kurono M, Mitani T, Ninomiya N, Ishiwata Y, Yokochi S, Asano K, Yamada K, Taki M, Meguro T, Minamitani M, Matumoto T, Shiokawa Y. Composition for Enhancing Biosynthesis of Interferon, U. S. Patent 5,260,056, 1993.
55. Schroeder H, Balassa J. Arsenic, germanium, tin, and vanadium in mice: Effects on growth, survival and tissue levels. J Nutr 1967;92:245-252.
56. Schwartz GN, Biegel JA, Fisher B, Klein I. Spirogermanium: Effects on hematopoietic stem cells and survival of normal and tumor-bearing mice. Proc Soc Exper Biol Med 1983;173:176-180.
57. Shinogi M, Masaki T, Mori I. Determination and biokinetics of germanium in mouse tissues by atomic absorption spectrometry with electrothermal atomization. J Trace Elem Electrolytes Health Dis 1989;3:25-28.
58. Slavik M, Blanc O, Davis J. Spirogermanium: A new investigational drug of novel structure and lack of bone marrow toxicity. Invest New Drugs 1983;1:225-234.
59. Song WS. Experimental study on prevention of the colorectal cancer by China medical stone and the organogermanium compound. Zhonghua Yu Fang Yi Xue Za Zhi 1993;27:286-289.
60. Suzuki F. Suppression of tumor growth by peritoneal macrophages isolated from mice treated with carboxyethylgermanium sesquioxide (Ge-132). Gan To Kagaku Ryoho 1985;12:2122-2128.
61. Suzuki F. Antitumor mechanisms of carboxyethyl-germanium sesquioxide (Ge-132) in mice bearing Ehrlich ascites tumors. Gan To Kagaku Ryoho 1987;14:127-134.
62. Suzuki F, Brutkiewicz RR, Pollard RB. Ability of sera from mice treated with Ge-132, an organic germanium compound, to inhibit experimental murine ascites tumours. Br J Cancer 1985a; 52:757-763.
63. Suzuki F, Brutkiewicz RR, Pollard RB. Importance ot T-cells and macrophages in the antitumor activity of carboxyethylgermanium sesquioxide (Ge-132). Anticancer Res 1985b;5:479-483.
64. Suzuki F, Brutkiewicz RR, Pollard RB. Cooperation of lymphokine(s) and macrophages in expression of antitumor activity of carboxyethylgermanium sesquioxide (Ge-132). Anticancer Res 1986;6:177-182.
65. Suzuki F, Pollard RB. Prevention of suppressed interferon gamma production in thermally injured mice by administration of a novel organogermanium compound, Ge-132. J Interferon Res 1984;4:223-233.
66. Takeuchi A, Yoshizawa N, Oshima S, Kubota T, Oshikawa Y, Akashi Y, Oda T, Niwa H, Imazeki N, Seno A, et al. Nephrotoxicity of germanium compounds: Report of a case and review of the literature. Nephron 1992;60:436-442.
67. Tanaka N, Ohida J, Ono M, Yoshiwara H, Beika T, Terasawa A, Yamada J, Morioka S, Mannami T, Orita K. Augmentation of NK activity in peripheral blood lymphocytes of cancer patients by intermittent Ge-132 administration. Gan To Kagaku Ryoho 1984;11:1303-1306.
68. Tao SH, Bolger PM. Hazard assessment of germanium supplements. Regul Toxicol Pharmacol 1997;25:211-219.
69. Tsutsui M, Kakimoto N, Axtell DD, Oikawa H, Asai K. Crystal Structure of "carboxyethylgermanium sesquioxide." J Am Chem Soc 1976;98:8287-8289.